XML 77 R113.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CAPITAL STOCK - Schedule of Performance Program Activities (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Expired, weighted average exercise price (in USD per share) $ 88.82 $ 104.21 $ 76.09
Employee-related Liabilities, Current $ 212 $ 177  
Conditional Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Nonvested, Beginning Balance, Shares (in shares)      
Nonvested, Ending Balance, Shares (in shares) 780,507    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Total compensation cost related to non-vested awards not yet recognized $ 2    
Weighted-average remaining life of unvested restricted stock units 3 months 18 days    
2019 Performance Program | Conditional Phantom Units      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Employee-related Liabilities, Current $ 26    
Performance Program | Conditional Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Nonvested, Beginning Balance, Shares (in shares) 1,347,000    
Granted, Shares (in shares) 345,000    
Vested, Shares (in shares) (510,000)    
Forfeited, Shares (in shares) (71,000)    
Expired, Shares (in shares) (330,000)    
Nonvested, Ending Balance, Shares (in shares) 781,000 1,347,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Non-vested Beginning Balance, Weighted Average Grant Date Fair Value (in USD per share) $ 49.58    
Granted, Weighted Average Grant-Date Fair Value (in USD per share) 32.75    
Vested, Weighted Average Grant-Date Fair Value (in USD per share) 45.62    
Forfeited, Weighted Average Grant-Date Fair Value (in USD per share) 53.96    
Expired, weighted average exercise price (in USD per share) 29.78    
Non-vested Ending Balance, Weighted Average Grant Date Fair Value (in USD per share) $ 52.69 $ 49.58  
Performance Program | Conditional Phantom Units      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Nonvested, Beginning Balance, Shares (in shares) 890,000    
Granted, Shares (in shares) 1,680,000    
Vested, Shares (in shares) (2,000)    
Forfeited, Shares (in shares) (248,000)    
Nonvested, Ending Balance, Shares (in shares) 2,320,000 890,000